Boundless Bio (BOLD) vs Fractyl Health (GUTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Boundless Bio (BOLD) has outperformed Fractyl Health (GUTS) over the past year, gaining 98.5% versus a loss of 74.8%. Fractyl Health is the larger company by market cap ($59.2 million vs $57.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | GUTS |
|---|---|---|
| Share price | $2.53 | $4.46 |
| Market cap | $57.55M | $59.18M |
| 1-day change | -1.94% | +5.46% |
| YTD return | +115.00% | -83.98% |
| 1-year return | +98.46% | -74.82% |
| EPS (TTM) | $-2.85 | $-10.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.16 | $29.34 |
| 52-week low | $0.961 | $4.14 |
| Distance from 52-week high | -20.04% | -84.80% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +58.10% | +1253.96% |
| Average volume | 182.04K | 156.16K |
| Shares outstanding | 22.75M | 13.26M |
| Employees | 28 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed GUTS by 173.3 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Fractyl Health
GUTS stock →Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Health Care · Medical/Dental Instruments · 100 employees
BOLD vs GUTS FAQ
Which is bigger, Boundless Bio or Fractyl Health?
Fractyl Health (GUTS) is larger, with a market capitalization of $59.18M compared with $57.55M for Boundless Bio (BOLD).
Which stock has performed better over the past year, BOLD or GUTS?
BOLD returned +98.46% over the past 12 months, compared with -74.82% for GUTS (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Fractyl Health in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Boundless Bio and Medical/Dental Instruments for Fractyl Health.